134 related articles for article (PubMed ID: 35504365)
1. Lifetime attributable risk of radiation induced second primary cancer from scattering and scanning proton therapy - A model for out-of-field organs of paediatric patients with cranial cancer.
Dell'Oro M; Short M; Wilson P; Peukert D; Hua CH; Merchant TE; Bezak E
Radiother Oncol; 2022 Jul; 172():65-75. PubMed ID: 35504365
[TBL] [Abstract][Full Text] [Related]
2. Modelling the influence of radiosensitivity on development of second primary cancer in out-of-field organs following proton therapy for paediatric cranial cancer.
Dell'Oro M; Wilson P; Short M; Peukert D; Bezak E
Br J Radiol; 2023 Oct; 96(1150):20230161. PubMed ID: 37660473
[TBL] [Abstract][Full Text] [Related]
3. Second cancer incidence risk estimates using BEIR VII models for standard and complex external beam radiotherapy for early breast cancer.
Donovan EM; James H; Bonora M; Yarnold JR; Evans PM
Med Phys; 2012 Oct; 39(10):5814-24. PubMed ID: 23039620
[TBL] [Abstract][Full Text] [Related]
4. Assessment of radiation-induced second cancer risks in proton therapy and IMRT for organs inside the primary radiation field.
Paganetti H; Athar BS; Moteabbed M; A Adams J; Schneider U; Yock TI
Phys Med Biol; 2012 Oct; 57(19):6047-61. PubMed ID: 22968191
[TBL] [Abstract][Full Text] [Related]
5. Assessment of long-term risks of secondary cancer in paediatric patients with brain tumours after boron neutron capture therapy.
Zhang X; Geng C; Tang X; Bortolussi S; Shu D; Gong C; Han Y; Wu S
J Radiol Prot; 2019 Sep; 39(3):838-853. PubMed ID: 31195386
[TBL] [Abstract][Full Text] [Related]
6. The risk of radiation-induced second cancers in the high to medium dose region: a comparison between passive and scanned proton therapy, IMRT and VMAT for pediatric patients with brain tumors.
Moteabbed M; Yock TI; Paganetti H
Phys Med Biol; 2014 Jun; 59(12):2883-99. PubMed ID: 24828559
[TBL] [Abstract][Full Text] [Related]
7. Secondary cancer risk assessments following the proton therapy of lung cancer as the functions of field characteristics and patient age.
Jia SB; Shamsabadi R
Int J Radiat Biol; 2024; 100(2):183-189. PubMed ID: 37747407
[TBL] [Abstract][Full Text] [Related]
8. Radiation dose and cancer risk to out-of-field and partially in-field organs from radiotherapy for symptomatic vertebral hemangiomas.
Mazonakis M; Tzedakis A; Lyraraki E; Damilakis J
Med Phys; 2016 Apr; 43(4):1841. PubMed ID: 27036581
[TBL] [Abstract][Full Text] [Related]
9. Risk estimation of second primary cancers after breast radiotherapy.
Santos AM; Marcu LG; Wong CM; Bezak E
Acta Oncol; 2016 Nov; 55(11):1331-1337. PubMed ID: 27379458
[TBL] [Abstract][Full Text] [Related]
10. Impact of lifetime attributable risk of radiation-induced secondary cancer in proton craniospinal irradiation with vertebral-body-sparing for young pediatric patients with medulloblastoma.
Suzuki S; Kato T; Murakami M
J Radiat Res; 2021 Mar; 62(2):186-197. PubMed ID: 33341899
[TBL] [Abstract][Full Text] [Related]
11. Secondary cancer-incidence risk estimates for external radiotherapy and high-dose-rate brachytherapy in cervical cancer: phantom study.
Lee B; Ahn SH; Kim H; Son J; Sung J; Han Y; Huh SJ; Kim JS; Kim DW; Yoon M
J Appl Clin Med Phys; 2016 Sep; 17(5):124-132. PubMed ID: 27685104
[TBL] [Abstract][Full Text] [Related]
12. Assessing the radiation-induced second cancer risk in proton therapy for pediatric brain tumors: the impact of employing a patient-specific aperture in pencil beam scanning.
Geng C; Moteabbed M; Xie Y; Schuemann J; Yock T; Paganetti H
Phys Med Biol; 2016 Jan; 61(1):12-22. PubMed ID: 26605679
[TBL] [Abstract][Full Text] [Related]
13. Low dose radiation therapy for COVID-19: Effective dose and estimation of cancer risk.
García-Hernández T; Romero-Expósito M; Sánchez-Nieto B
Radiother Oncol; 2020 Dec; 153():289-295. PubMed ID: 33065184
[TBL] [Abstract][Full Text] [Related]
14. Scattered dose to radiosensitive organs and associated risk for cancer development from head and neck radiotherapy in pediatric patients.
Kourinou KM; Mazonakis M; Lyraraki E; Stratakis J; Damilakis J
Phys Med; 2013 Nov; 29(6):650-5. PubMed ID: 22921884
[TBL] [Abstract][Full Text] [Related]
15. Lifetime attributable risk of radiation-induced secondary cancer from proton beam therapy compared with that of intensity-modulated X-ray therapy in randomly sampled pediatric cancer patients.
Tamura M; Sakurai H; Mizumoto M; Kamizawa S; Murayama S; Yamashita H; Takao S; Suzuki R; Shirato H; Ito YM
J Radiat Res; 2017 May; 58(3):363-371. PubMed ID: 27789564
[TBL] [Abstract][Full Text] [Related]
16. The risk for developing a secondary cancer after breast radiation therapy: Comparison of photon and proton techniques.
Paganetti H; Depauw N; Johnson A; Forman RB; Lau J; Jimenez R
Radiother Oncol; 2020 Aug; 149():212-218. PubMed ID: 32464163
[TBL] [Abstract][Full Text] [Related]
17. MONTE CARLO SIMULATION OF OUT-OF-FIELD ORGAN DOSES AND CANCER RISK IN TANZANIA FOR RADIATION THERAPY OF UNILATERAL RETINOBLASTOMA USING A 60Co UNIT.
Suleiman SA; Qi Y; Pi Y; George Xu X
Radiat Prot Dosimetry; 2018 May; 179(3):263-270. PubMed ID: 29216393
[TBL] [Abstract][Full Text] [Related]
18. The risk of second primary cancers due to peripheral photon and neutron doses received during prostate cancer external beam radiation therapy.
Bezak E; Takam R; Yeoh E; Marcu LG
Phys Med; 2017 Oct; 42():253-258. PubMed ID: 28302493
[TBL] [Abstract][Full Text] [Related]
19. Assessment of uncertainties in radiation-induced cancer risk predictions at clinically relevant doses.
Nguyen J; Moteabbed M; Paganetti H
Med Phys; 2015 Jan; 42(1):81-9. PubMed ID: 25563249
[TBL] [Abstract][Full Text] [Related]
20. Risk of developing second cancer from neutron dose in proton therapy as function of field characteristics, organ, and patient age.
Zacharatou Jarlskog C; Paganetti H
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):228-35. PubMed ID: 18571337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
